An 8-amino-acid cyclic peptide analog of somatostatin with a half-life 30x longer than native somatostatin. FDA-approved for acromegaly, carcinoid syndrome, and neuroendocrine tumors. One of the most clinically important therapeutic peptides in oncology.
Octreotide is a synthetic 8-amino-acid cyclic peptide that mimics the pharmacological effects of the natural hormone somatostatin (SST, 14 amino acids) while having a 30x longer half-life. It was developed by Sandoz (now Novartis) and approved by the FDA in 1988.
Native somatostatin is a powerful inhibitor of growth hormone, insulin, glucagon, and many GI hormones, but its extremely short half-life (3 minutes) made it clinically impractical. Octreotide solved this by incorporating D-amino acids (D-Phe, D-Trp) and a disulfide bridge that resist enzymatic degradation while preserving somatostatin receptor binding.
Octreotide activates somatostatin receptors, particularly SSTR2 (highest affinity) and SSTR5. These are Gi-coupled GPCRs whose activation inhibits adenylyl cyclase, reducing intracellular cAMP. In endocrine cells, reduced cAMP decreases hormone secretion. In tumor cells expressing SSTRs, octreotide inhibits proliferation through cell cycle arrest and may induce apoptosis.
| Pathway | Effect | Significance |
|---|---|---|
| GH suppression | Inhibits pituitary GH release via SSTR2 | Treatment of acromegaly (GH excess) |
| GI hormone inhibition | Reduces secretion of serotonin, VIP, gastrin, and other gut hormones | Controls carcinoid syndrome symptoms (flushing, diarrhea) |
| Antiproliferative | Arrests tumor cell cycle and inhibits angiogenesis | Stabilizes neuroendocrine tumor growth (CLARINET/PROMID trials) |
| Variceal bleeding | Reduces splanchnic blood flow via vasoconstriction | Emergency treatment for acute variceal hemorrhage |
| D-amino acid stability | D-Phe and D-Trp resist protease degradation | 30x longer half-life than native somatostatin (1.5h vs 3 min) |
| Study | Design | Findings | Level |
|---|---|---|---|
| Acromegaly | Extensive RCTs, standard of care | Normalizes GH and IGF-1 in 50-70% of patients. FDA-approved first-line medical therapy. | Level I |
| Carcinoid syndrome | Phase III, PROMID/CLARINET | Controls flushing and diarrhea in >70% of patients. Delays tumor progression. | Level I |
| Neuroendocrine tumors | CLARINET trial, n=204 | Octreotide LAR significantly prolonged progression-free survival vs placebo in GEP-NETs | Level I |
| Variceal bleeding | RCTs | Reduces portal pressure and controls acute hemorrhage. Guideline-recommended. | Level I |
| Acromegaly diagnosis | Octreotide suppression test | Used diagnostically to confirm GH suppressibility and predict surgical outcomes | Level I |
GI side effects: Nausea, diarrhea, abdominal pain in 30-50% of patients initially. Usually improves over weeks.
Gallstones: Octreotide inhibits gallbladder contraction, increasing gallstone risk (~25% at 1 year). Ultrasound monitoring recommended.
Glucose effects: Can both increase and decrease blood glucose (inhibits both insulin and glucagon). Monitor in diabetic patients.
Injection site pain: SC injection can be painful. LAR (long-acting release) IM formulation reduces injection frequency to monthly.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Sandostatin (SC, 1988), Sandostatin LAR (monthly IM depot). Multiple indications. |
| Biosimilars | Generic octreotide and biosimilar LAR formulations now available |
| WHO | Essential Medicine for acromegaly and neuroendocrine tumors |